# US 2024/0360101 A1 · Pharmaceutical salts of a chk-1 inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0360101 A1
- Document ID: US20240360101A1
- Status: Published application
- Kind: A1
- Application number: 18/566,777
- Filed: 2022-06-01
- Published: 2024-10-31
- Earliest claimed: 2021-06-03
- Assignees: Sentinel Oncology Limited; Pharmaengine, Inc.
- Applicants: Sentinel Oncology Limited; Pharmaengine, Inc.
- Inventors: Meriel MAJOR; Stuart TRAVERS; Jake PARKER; Julian NORTHEN
- Web page: https://patentgrep.com/patent/US20240360101A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4858: {Organic compounds}
- A61K 31/497: containing further heterocyclic rings
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 35/00: Antineoplastic agents
- C07C 55/08: Malonic acid
- C07C 309/04: containing only one sulfo group
- C07C 309/29: of non-condensed six-membered aromatic rings
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts. Also provided are particular crystalline forms of the salts, methods for the preparation of the salts, pharmaceutical compositions containing the salts and their therapeutic uses.

## Claims

### Claim 1

A pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts.

### Claim 2 (depends on 1)

A pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile according to claim 1 which is a maleate salt.

### Claim 3 (depends on 1)

A pharmaceutically acceptable salt according to claim 1 having a salt ratio (molar ratio of acid:free base) of approximately 1:1.

### Claim 4 (depends on 1)

A pharmaceutically acceptable salt according to claim 1 which is from 50% to 100% crystalline.

### Claim 5 (depends on 2)

A pharmaceutically acceptable maleate Pattern B salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile according to claim 2 which has an XRPD spectrum characterised by major ° 2Th (° 2Theta) peaks at 6.9±0.2° and/or 26.4±0.2° and/or 11.8 0.2° and/or 17.9±0.2°.

### Claim 6 (depends on 2)

A pharmaceutically acceptable maleate salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile according to claim 2 which is a Pattern B salt having an XRPD spectrum substantially as shown in FIG. 25.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile as defined in claim 1, and a pharmaceutically acceptable excipient.

### Claim 8 (depends on 1)

A method for the treatment of cancer, which method comprises administering to a patient a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile as defined in claim 1.

### Claim 9 (depends on 1)

A pharmaceutical combination comprising a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile as defined in claim 1 and another therapeutically active agent.

### Claim 10 (depends on 1)

A method of preparing a pharmaceutically acceptable salt as defined in claim 1; which process comprises dispersing 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile in tetrahydrofuran to form a mixture, heating the mixture to an elevated temperature in the range from 45° C. to 65° C. (e.g. from 55° C. to 65° C. and particularly approximately 60° C.), adding a required amount of an acid to the mixture; maintaining the mixture at or near the elevated temperature for a defined period and cooling the mixture to allow isolation of the pharmaceutically acceptable salt.

### Claim 11 (depends on 1)

A method of preparing a pharmaceutically acceptable salt as defined in claim 1; which process comprises dispersing 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile in a mixture of tetrahydrofuran and acetonitrile (e.g. a 1:1 mixture) to form a mixture, heating the mixture to an elevated temperature in the range from 45° C. to 55° C. (e.g. approximately 50° C.), adding a required amount of an acid to the mixture; maintaining the mixture at or near the elevated temperature for a defined period and cooling the mixture to allow isolation of the pharmaceutically acceptable salt.

### Claim 12 (depends on 1)

A method of preparing a pharmaceutically acceptable salt as defined in claim 1; which process comprises dispersing 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile in a mixture of tetrahydrofuran and water (e.g. wherein the mixture contains from 75% to 97% (v/v) tetrahydrofuran and from 3% to 25% (v/v) water, and more preferably approximately 95% (v/v) tetrahydrofuran and approximately 5 (v/v) water) to form a mixture, heating the mixture to an elevated temperature in the range from 45° C. to 65° C. (e.g. approximately 50° C. to 60° C.), adding a required amount of an acid to the mixture; maintaining the mixture at or near the elevated temperature for a defined period and cooling the mixture to allow isolation of the pharmaceutically acceptable salt.

### Claim 13 (depends on 10)

A method according to claim 10 wherein the acid is maleic acid and the resulting pharmaceutically acceptable salt is a maleate salt.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the maleate salt is maleate salt Pattern A salt.

### Claim 15 (depends on 14)

A method according to claim 14 which further comprises converting the Pattern A maleate salt to a Pattern B maleate salt by conditioning the Pattern A salt in an atmosphere of greater than 50% relative humidity.

### Claim 16

(canceled)

### Claim 17 (depends on 2)

A pharmaceutically acceptable salt according to claim 2 having a salt ratio (molar ratio of acid:free base) of approximately 1:1.

### Claim 18 (depends on 2)

A pharmaceutically acceptable salt according to claim 2 which is from 50% to 100% crystalline.

### Claim 19 (depends on 2)

A pharmaceutical composition comprising a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile as defined in claim 2, and a pharmaceutically acceptable excipient.

### Claim 20 (depends on 11)

A method according to claim 11 wherein the acid is maleic acid and the resulting pharmaceutically acceptable salt is a maleate salt.

### Claim 21 (depends on 12)

A method according to claim 12 wherein the acid is maleic acid and the resulting pharmaceutically acceptable salt is a maleate salt.
